Bernard J. Zovighian - 08 Dec 2025 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CEO, Director
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
08 Dec 2025
Transactions value $
-$651,216
Form type
4
Filing time
10 Dec 2025, 18:58:43 UTC
Previous filing
03 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Zovighian Bernard J CEO, Director ONE EDWARDS WAY, IRVINE Linda J. Park, Attorney-in-Fact 10 Dec 2025 0001665141

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $1.5M +25.4K +31.31% $59.26 106K 08 Dec 2025 Direct F1
transaction EW Common Stock Sale -$1.83M -21.5K -20.21% $85.21 84.8K 08 Dec 2025 Direct F1, F2
transaction EW Common Stock Gift $0 -3.86K -4.55% $0.00 81K 09 Dec 2025 Direct
transaction EW Common Stock Gift $0 +3.86K +44.94% $0.00 12.5K 09 Dec 2025 By Trust
transaction EW Common Stock Sale -$322K -3.86K -31% $83.45 8.6K 10 Dec 2025 By Trust F1
holding EW Common Stock 3.61K 08 Dec 2025 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -25.4K -50% $0.00 25.4K 08 Dec 2025 Common Stock 25.4K $59.26 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025.
F2 This transaction was executed in multiple trades at prices ranging from $84.63 to $85.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3 These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.